春立醫療(01858.HK)擬斥1,750萬人幣購舒捷醫療70%股權
春立醫療(01858.HK)(688236.SH)公布,擬以1,100萬元人民幣(下同)受讓徐林峰及陳協合計持有的舒捷醫療60.25%股權。此外,公司向舒捷醫療增資650萬元。完成後,舒捷醫療註冊資本增至為2,650萬元,春立醫療持有舒捷醫療70%的股權。
舒捷醫療主要從事手術動力裝置的研發、生產和銷售的科技型企業,主要產品包括手術動力裝置整機及配件等,主要用於外科手術中對骨組織、軟組織的切除、磨削、鋸切、修整等,現有產品主要輔助於骨科手術。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.